Abstract 839P
Background
Amulirafusp alfa (IMM0306) is a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα on both heavy chains. It exerts excellent cancer killing effect by activating both macrophages and natural killer cells via blockade of CD47-SIRPα interaction and FcɣR engagement. Here, we report the safety and efficacy results in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) from a phase II study (NCT05805943).
Methods
Eligible patients with FL Grade 1-3a received intravenous Amulirafusp alfa once a week of a 28-day treatment cycle with dose of 2.0 mg/kg until disease progression or intolerable toxicity. Safety was evaluated per the Common Terminology Criteria for Adverse Events version 5.0. Tumor assessments were performed by Lugano 2014. The primary endpoint was objective response rate (ORR). The secondary endpoints including disease control rate (DCR), progression free survival (PFS), and safety.
Results
As of Mar 14, 2024, 16 pts with FL were enrolled. The median age was 61 years old with 10 (62.5%) males. The median prior lines of therapy were 4. All 16 pts received previous anti-CD20 therapy. The most common treatment related adverse events (TRAEs) were lymphocyte (LYM) decreased (68.8%), platelet (PLT) decreased (50.0%), white blood cell (WBC) decreased (43.8%), anemia (43.8%) and absolute neutrophil count (ANC) decreased (31.3%). ≥ Grade 3 TRAEs occurred in 62.5% of pts. The most common ≥ grade 3 TRAEs were LYM decreased (50.0%), PLT decreased (18.8%), ANC decreased (18.8%) and pneumonia (18.8%). 18.8% of pts experienced serious TRAEs, all was pneumonia, in which 2 pts were recovering and 1 pts recovered without sequelae. No adverse event led to drug reduction, discontinuation or death. Among 15 efficacy evaluable pts with R/R FL, the ORR and DCR assessed by investigator was 33.3% and 66.7%, respectively. With a median follow-up of 5.72 months, the PFS rate at 9 months was 58.3%.
Conclusions
Amulirafusp alfa (IMM0306) was well-tolerated and presented robust preliminary anti-tumor activity in pts with R/R FL. This phase II study is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Funding
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Disclosure
W. Meng: Financial Interests, Personal, Affiliate: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Z. Wang: Financial Interests, Personal, Full or part-time Employment: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. All other authors have declared no conflicts of interest.
Resources from the same session
707P - Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study
Presenter: Edgar Israelyan
Session: Poster session 09
708P - The Empower Pathway: An audit of the first 150 patients. Enhanced personalised care of testicular cancer survivors
Presenter: Penny Champion
Session: Poster session 09
817P - A machine learning algorithm utilizing clinicopathologic parameters for extranodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 09
Resources:
Abstract
818P - The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy
Presenter: Z.L.Rana Kaplan
Session: Poster session 09
819P - Efficacy and safety of orelabrutinib plus R-CHOP-like regimens for treatment-naïve diffuse large B-cell lymphoma with double expression
Presenter: Wei Wan
Session: Poster session 09
820P - Second primary malignancies and disease transformation in symptomatic patients with Waldenstrom’s macroglobulinemia: Outcomes of a population-based analysis
Presenter: Vasiliki Spiliopoulou
Session: Poster session 09
821P - Circulating chromosomal alterations in lymphoid malignancies
Presenter: Rosalie Griffin
Session: Poster session 09
822P - Preliminary results from a phase Ib study of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: Lijuan Deng
Session: Poster session 09
823P - The bone marrow immune ecosystem shapes acquired resistance to daratumumab in plasma cell myeloma
Presenter: Yun Wang
Session: Poster session 09
824P - FLT3-ITD induces immune escape in AML via up-regulating CD47 expression and decreased phagpcytic ability of macrophages
Presenter: Shuzhao Chen
Session: Poster session 09